Good morning. Good to see you. The format is that David will step us through the presentation that has been released this morning to ASX. After the presentation, we will then open up the floor to Q&A. If you would like to ask a question, you can do so at any time by typing it into the chat function in the ribbon at the bottom of your screen. We will get through as many questions as we can in the time that we have. For now, though, I will start our screen share of the presentation and ask David to get us on the road. Over to you, David. Good morning, everyone, and welcome to our webinar. Can you all see the screen? Yes, I hope so. I just wanted to start by providing a brief overview to what I am going to discuss in a bit more detail today. We have built a really strong foundation to drive growth. The commercial milestones that we have achieved over the last nine months are really quite significant. We have reorganized the business and significantly reduced our operating cost. We have secured the Healius distribution partnership, which is the most important path for commercial success. We have commenced the national rollout of PromarkerD and PromarkerEso, and also have now independently validated the PromarkerEndo test, and we plan to commercially launch that sometime between January and March of next calendar year. Moving forward, and to drive our growth, we are going to have to do a number of really important things. The first one is to continue to increase awareness and adoption of our Promarker tests in Australia. We are, as I mentioned just previously, we need to launch the PromarkerEndo test, and we are on track to do that. We will look to appoint an initial U.S. distributor between now and the end of June of next year. We will continue to advance reimbursement both in Australia and the U.S., and we have made some good progress in both of those markets to date. And we will continue to improve our laboratory efficiency and capacity, most importantly to deal with the volume of tests in Australia, and subsequently to also do the same at our lab in California. In order to fund those growth initiatives, we have launched an SPP to raise AUD 5 million. As you are aware, that SPP opens today and will close on the 25th of November, and subject to achieving the AUD 5 million, we will be fully funded for the next 12 months up until October 2027. Next slide, please, Jane. I would just like to provide a brief overview to our business to clearly define what it is we do. We target unmet clinical needs, and if you look at our three core tests, they are dealing with some of the most prevalent diseases in the world. We have a proprietary platform that discovers disease associated with protein biomarkers, and what is really important about that is the way this is done is once we have identified these protein biomarkers, we can identify the changes in signal that indicate disease. That platform has been based on years of development and with some very experienced people in our business to not only do that for the three tests that we have, but also to help continue to identify new unmet clinical needs, identify those protein biomarkers, and build a development pipeline for the future. As I mentioned previously, we have two labs, one here in Australia, in Perth, which is NATA accredited, and the other one in the U.S., which is CLIA and CAP accredited. They are really important to us because our current business model, which I will also discuss in subsequent slides, is that we will continue to do all the tests for Australia in our lab in Perth, and all the tests for the U.S. in our lab in California. Moving forward to drive market access, we will adopt a distributor model as we have here with Healius, and we will do exactly the same thing in the U.S. Initially, our tests in Australia will be private pay, but we are absolutely pursuing reimbursement for all three tests because affordability does matter. As I mentioned earlier, our next other key milestone is to appoint a distributor in the U.S. Next slide, please, Jane. As I've mentioned, we have four tests. The three Promarker tests, which I will discuss in a subsequent slide, and OxiDx. OxiDx is currently under strategic review, and we are currently assessing the technology, the business models, and the commercial models. As soon as we have completed that strategic review and we have a clear path forward, we'll inform everyone of the outcome of that. Next slide, please, Jane. Just to do a bit more of a deep dive into our three Promarker tests. PromarkerD is a diagnostic test that identifies patients with diabetes at a high risk of diabetic-related kidney disease up to four years in advance. Why does this matter? Because early intervention does lower the downstream costs of kidney disease, because kidney disease results in either two things, dialysis or transplant, both of which are incredibly extensive interventions. We have just recently completed a health economics review of PromarkerD, and we will do the same for PromarkerEso and PromarkerEndo. What that tells us is our PromarkerD test is incredibly valuable, and we will use that as part of our reimbursement strategy to achieve Medicare funding. PromarkerEso is a diagnostic test for people with chronic reflux and is a rule-out test for esophageal cancer. Why this test is really important is because it avoids the unnecessary and expensive invasive procedures of endoscopy. I think what also should be noted as well is that many people do not like having invasive procedures, and it is not uncommon to even go to your gastroenterologist and they say, "We think you need to have an endoscopy. Please book it with the receptionist on your way out," and the person doesn't book the test. It's very common practice. With this simple blood test, we believe that more people will be engaged in really assessing and ruling out whether or not they have esophageal cancer. The third test, PromarkerEndo, is a diagnostic test for women with symptoms that are suggestive of endometriosis. One in eight women suffer from endometriosis, and living with the pain and uncertainty and waiting 6-8 years for diagnosis is way too long. Faster diagnosis and more effective management by the clinician, whether it be the GP or your gynecologist, is really important to help these women that are suffering from endometriosis. As I mentioned with PromarkerD and as I mentioned earlier, we will pursue Medicare funding for all three tests because affordability matters, and we need to make sure that our tests are available to as many people that could benefit from them as possible. Next slide, please, Jane. We have assessed the market potential for each of these three tests in both Australia and the U.S., and the opportunities are really significant, both here and in the U.S. We have based our forecast on achieving a Serviceable Obtainable Market, the SOM, which is actually the smaller number in each of the bar charts for each of the tests. In Australia, PromarkerD and PromarkerEso, based on the current user pay price, has indicative revenues of AUD 25 million per annum. That is just for the first two tests, and that is an order of magnitude greater in the U.S. We believe that with reimbursement, and based on the health economics work we have done to date and continue to do, we believe that we will be able to achieve test volumes actually closer to the serviceable available market, which is the second bar in the chart. When you consider all of this, we believe that this opportunity for our three core tests, and that is why we are focusing absolutely on making these three tests commercially successful and attainable to patients that could benefit from them as our number one priority, both in Australia and then subsequently in the U.S. Next slide, please, Jane. As I mentioned earlier, the Healius distribution partnership is an absolutely critical foundation to our success in the Australian market. Prior to this, we had no clear path to commercial success and path to market for our tests. When we looked at developing the Healius distribution partnership, we looked at a few things, right? We needed national reach and distribution. We needed access to GPs and specialists who could refer the test to their patients. We did not want to build the network ourselves, and we needed to be able to integrate these tests into standard clinical routine practices, and Healius offered all of that to us. What is really important about what we will do is we will continue to do the tests in Perth, so we will perform the tests. Healius will collect the bloods, they will send the bloods to us in Perth, we will do the test, we will issue the reports into their system, and in turn, those reports, via their systems, will go to the doctor that has ordered the test. Healius has about 1,900 collection centers all over the country. As I have mentioned, they will collect the specimens. We have launched, as you are aware, PromarkerD and PromarkerEso. All of their collection centers have been trained, all of their business development managers have been trained, and have commenced the process of generating awareness with all of their referring clinicians, whether they be GPs or specialists, starting that education process, explaining them how to do the test, how to order the test, and obviously, the value proposition of the test to the patient and to them in terms of their clinical practice. That process was just started a few weeks ago. We are now working through that, and we expect sales to come sometime soon. In terms of that commercial rollout, I've just mentioned that, just to be clear, the initial private pay for PromarkerD and PromarkerEso prices have been set, and PromarkerEndo, as I mentioned earlier, will launch sometime between January and March of next year. That pricing is still to be confirmed. Next slide, please. In terms of our execution plan, and I believe that this was shared with you for the first time, probably around April of this year, March, April of this year, when I launched our strategic plan. I've now been in the role for just on nine months. Every milestone that we have set out to achieve in our strategic plan has been achieved, and has been achieved ahead of schedule. The next critical milestones will advance our growth potential, and they're really important as we drive to continued commercial success in Australia, and which includes reimbursement both here and in the U.S., but most importantly, the next also critical milestone beyond the launch of PromarkerEndo in Australia is the appointment of an initial distributor in the U.S. I'm really confident, based on the last nine months, based on the capability of the team, what we've been able to achieve in a very short time, that we will be able to achieve the milestones as per the schedule. Next slide, please, Jane. As mentioned in the beginning, as you're aware, we've launched a share purchase plan to raise AUD 5 million to fund our growth. We've achieved, as I've now mentioned a few times, a number of commercial milestones today, but most importantly, the Healius partnership, the Australian rollout of PromarkerD and PromarkerEso, and the next most important milestone of the launch of PromarkerEndo. Having three products to sell is absolutely critical because that is our core portfolio, and having a path to sell them is the next most important thing, and all of those milestones have been achieved. As I mentioned, we plan to raise AUD 5 million. The offer of the share will be at AUD 0.10, which is a 12.2% discount to the five-day VWAP. The maximum application for each existing shareholder is AUD 30,000. We are targeting to achieve AUD 5 million, or to raise AUD 5 million, and we will also provide a one-for-one attaching option. As I've mentioned earlier, that AUD 5 million will fund all of our activities for the next 12 months. The offer opens today and will close on the 25th of November. Next slide, please, Jane. As I've just mentioned, we plan to raise AUD 5 million. Our current sources of funds, as at the end of September, we had AUD 1.8 million cash. We received, subsequent to that, an R&D tax refund of AUD 2 million, so we have AUD 3.8 million, plus other income gets us to AUD 4.1 million. With the proceeds from the SPP, we will have AUD 9.1 million. As I've mentioned now, that will fund us for the next 12 months. Those funds will be used primarily to drive our growth on four key things: commercial execution, U.S. market entry, clinical evidence to support awareness and adoption, and also to support reimbursement, and the fourth one is to drive reimbursement both in Australia and also in the U.S. With that, thank you very much for your attention, and I'm happy to now open up to questions. Thanks, David. Okay, with that, we'll open up the floor to questions, and I can see we've already got quite a number in the queue, so thanks to everyone who has already dropped some in. I'll note that we received a number via email as well, so thank you to all those who've written in, and we'll get through as many as we can. Okay, so first one for you, David. Have we made any early sales of either of the Promarker products at this stage? Yeah. As I've mentioned previously, once we launched PromarkerD and PromarkerEso into the market, what we then need to do is go out to all of Healius' GPs and specialists and educate them on the test, what the test does, why it's of clinical value, how it works, how much it costs, and they've got 1,900 collection centers, so you can imagine how many GPs and specialists they have, tens of thousands within their cohort, and they need to educate them all on that. They've started that process as part of the launch. Once that's complete, and it doesn't get done all at once, it's all being done in parallel across the country, in all states, in all territories, in all regions. Once that's done, then those doctors, whether they be GPs or specialists, then need to wait, either contact their patients who they believe need to benefit from these tests or wait for the presenting patient to come in and then communicate with them. So we expect to start to see sales of PromarkerD and PromarkerEso in the near future. Okay, thank you. Following on from that, what does success look like for Healius by, say, June 2027? A very good question. As I've said to many people before, this is a marriage made in heaven. We have three innovative tests that deal with diabetes, chronic reflux, and endometriosis. The populations just in Australia that suffer from these diseases are really significant. The opportunity for Healius, who have an incredible network and business, is to go out to their GPs, referring specialists, and provide these tests to them. If that question is a surrogate for how many tests are they going to sell, well, at this stage, we can't tell you or share that information. But what I can tell you is that the sales incentive plan have been put in place for all of the Healius sales reps and business development managers. We have a forecast that I'm very confident will be achieved, and that I think in the first six months of the launch of these two tests, followed at the beginning of next calendar year with PromarkerEndo, will really put both us and Healius in a good position in terms of sales. Okay. Thank you. In some cases, some of the questions cross over a little bit, so I may have asked one already, and then I'll try to couple some. We talked a little bit about how many PromarkerD and PromarkerEso tests have been processed since September, and demand for the national rollout. Follow-on question here, did any of the September quarter's AUD 264,000 in customer receipts come from these tests? And will Proteomics commit to reporting paid test numbers each quarter? Yeah, the short answer of that is no, because we just released, start, commence the launch of those two tests. As I mentioned, there is a lot of work that needs to be done to generate awareness amongst the clinicians. That work is underway, and so far, so it is being successful, and we are getting very positive feedback. That is the first part of the question. The second part of the question is, will we share sales with the market? Well, every quarter, we have to release a 4C, which includes our revenue, and that will be declared in that. Thank you. David, on the SPP, got a whole range of topics here. David, will you personally participate in the SPP with your own money? If so, how much? Have any other directors confirmed their intention to participate? Yeah. Firstly, all directors that are eligible to participate in the SPP will take up their full allotment. That is the first part. Second part is, what I have decided to do, subject to board approval and shareholder approval at the AGM, is to rather than take my STI in cash, I will take it in shares. That equates to AUD 108,000, which I will be directly investing through that mechanism. David. Okay. Coming back to the PromarkerEndo test now. We have got a few questions on this. "For me, detecting stage 1 disease was a major attraction of PromarkerEndo. How reliable is it at that stage? For women with stage 3 to 4 disease who may still need surgery, what does the test add that justifies the extra cost? Okay. Just to take a step back from that, I think it's really important, and I said this earlier, but I'm just going to reiterate it again. One in eight women suffer from endometriosis in this country, right? They're living with the pain and uncertainty, waiting 6-8 years to diagnosis, and that's far, far too long. I'm not sure whether any of you have had the chance to see the article that was in The West Australian last week, and it's been covered on Nine News across the whole country, so please go onto our website and have a look at that article. You can really get a sense of how debilitating this disease is and how it affects so many women, and for how long they go unserved or undiagnosed. Now, stage 1 diagnosis is important to be able to provide. Well, actually, you know what? It doesn't matter what stage you have, whether you have stage 1, stage 2, stage 3, stage 4, these are all women that are going through each of these four stages that are waiting between 6-8 years to be diagnosed. The really important part of the current standard of care and clinical protocol is once you get to the stage where the doctors decided that you need to have a laparoscopy, the really unfortunate thing about that intervention is that quite often they do a laparoscopy and they don't identify endometriosis. We know that there are many, many women that have had a laparoscopy and endometriosis was not identified when they've gone through that very invasive surgical procedure. The question that was asked, does it add value to those peoples with advanced endometriosis? Well, the reality is they don't know what level of endometriosis, what stage they're at, right? They believe they might have endometriosis, and the doctors have not diagnosed it yet. What becomes really important with our simple blood test is we can indicate to a high degree of confidence whether or not they do have endometriosis. Why that becomes really important is because if you're then going to your gynecologist who has deemed it important to do a laparoscopy, and you've had this blood test that says there's a very high chance you have endometriosis, when they go in, if they don't see anything initially, they're going to look a whole lot harder because they're going to be a lot more confident there's something there that they need to look for, as opposed to going in, looking really hard, not finding it, and then closing you up. This test is invaluable to the armamentarium or the battery of tests or battery of diagnostic procedures that are used to diagnose women with endometriosis. Dare I say, it's probably the most important one. Thanks, David. Then a follow-up question, I guess relating to the recent update that was put out. Can and will the PromarkerEndo testing be improved, particularly in the early stages of the disease? Yeah. The short answer is that's actually what we plan to do. We will continue with both, all of our three Promarker tests. We will always continue to refine and improve those tests, as we will with PromarkerEndo. One of the biggest challenges with endometriosis, especially in the very early stage, is it's really hard to detect. We know that. That's one of the reasons why people are waiting so long, or women are waiting so long. But I think it's really important to recognize that it's not only women with stage 1 endometriosis who are waiting a long time for a diagnosis. Women with stage 2, 3, and 4 are also waiting a long time for diagnosis. But we will continue to evolve these tests and continue to advance them to improve them further. Thank you. Question on the use of funds. Is any of the AUD 2 million research and development budget going towards brand new diagnostic tests outside the existing portfolio? If OxiDx, question one. And then if OxiDx is sold, what else is coming through the pipeline? Yeah. Three things. R&D funding rebate is not quarantined to R&D. It's a refund for the monies spent in the past, not necessarily how we need to use our funds for the future. That's the first thing. When I talked about the uses of funds, all of that AUD 9.1 million, which will fund us through for the next 12 months, will be used for commercial execution, U.S. market entry, reimbursement, continued product development, as per the previous question, and product, I shouldn't say product development/refinement, as per the previous question. So, we'll use those funds for all of those things. I touched on before about the pipeline and the incredible capability this organization has to identify protein biomarkers. We have this incredible capability that's been set up for many years now, and so there is a pipeline of new tests that we plan to develop. But what is really important at this stage is that we focus on commercializing the three core tests that we have and generating returns for those three core tests before we divert any of our resources to developing new tests. What I can say is that we have a list of tests, and as soon as we are starting to achieve commercial success with our three core Promarker tests, then will be the time to continue to develop the pipeline. In relation to the OxiDx, we are in the process of, as I have mentioned, undertaking a strategic review. OxiDx is a startup, right? It is a great concept that identifies the oxidative stress in both horses, particularly racehorses, is the target market, and elite athletes. We need to develop the technology to do the test. We have developed the science, which is really strong. We need to develop the technology to do the test. We need to determine what is the most appropriate business model which relates to the technology, and then we need to look at the commercial model to make this a success, and then we need to work out how we are going to fund that and whether we can fund that. So, that is still under review. We are working on that regularly to try and come to a decision as soon as possible. Thank you. Okay, couple of questions on the SPP because we have got a few here, and I will sort of try to roll them up. Why is not the company doing an institutional placement in parallel with the SPP? Good question. We looked at all the paths to raise capital, and what we decided was the best path would be via an SPP, in particular to reward our loyal shareholders with the chance to not only get a share at a discount to market, but also, buy shares at discount to market, but also to provide them with an option attached to each of those shares. So, that is the reason why we went down that path. We did explore all of our options, and we keep all of our options open in the future too. Thank you. Just some comments about the share price at the moment relative to the SPP price. Obviously, there is that option involved in the mix as well, which comes with its own inherent value, and there would be a Black-Scholes calculation in the booklet that is being launched today. A question here, if the SPP raises substantially less than AUD 5 million, what might be delayed? Yeah. We will cross that bridge when we come to it, or if we come to it. I am confident that we will raise the funds that we need because we have achieved an enormous amount over the last nine months. We have a really solid foundation from which we can springboard into commercial success. We have all the commercial success building blocks now in place. Actually, where we sit at the moment, this is the best time to invest in this business because everything is positive before us. We have, as I said, our commercial foundation is strong. We have a clear path to market. We have two tests in the market already. We have a third PromarkerEndo, which has a huge amount of awareness associated with it, which has now been independently validated on. That is good to go. We are now just refining some of the, refining, I say, the putting in place the clinical and regulatory requirements so that we can bring that to market as soon as possible. Thanks, David. Okay, just a comment here from somebody, which I will read out because I think it illustrates the importance of the Endo test. "As someone with Endo, I cannot tell you how valuable it is to know you have Endo. You cannot overstate the mental health benefit of actually having that information. The test would have been life-changing for me." Thank you for those comments. Yeah, I guess that harks back to the question earlier about the value that you could add. Yeah. Yeah. I would just like to also thank that person or that woman for her comment. I've had the opportunity over the last nine months to meet a lot of women with endometriosis. It is absolutely a debilitating disease, and the pain a woman goes through, the uncertainty, the mental anguish, the depression that these women experience, not only through the pain, but also through no one recognizing that they have a problem or thinking it's something else. For me, having this test and thinking about some of the early questions that have been asked about endometriosis, anything we can provide to these women to help them go onto the right path for diagnosis and treatment is really going to change people's lives. Ultimately, that's why we do what we do. That's why I do what I do. That's why I've been in healthcare for 25 years. I love this industry for one reason and one reason only. We help people live better lives, right? Endometriosis is a really good example of that. Yeah, I absolutely agree. I've got a couple of friends going through the same process at the moment, and actually understanding a diagnosis is huge, after decades, in some cases, of suffering and not knowing why. Okay, back to the Q&A. You will not have reimbursement for at least 12 months, as the application hasn't been lodged yet. Why is there no urgency in getting this application in, or is there something else holding you back? Right. There is absolutely an urgency in applying for reimbursement. As I've mentioned multiple times today, reimbursement in Australia, in particular, is one of our four key priorities over the next 6- 12 months for each of our three tests, for PromarkerD, PromarkerEso, and PromarkerEndo. There is nothing holding us back at all. We are working on that diligently. It's a long process. It's a complicated process. As I mentioned, we are starting the process on all three tests. It will take some time, but there are lots of avenues that we can pursue prior to reimbursement with each of our three tests, and we are looking at different avenues as well. But as I mentioned before, pursuing Medicare funding for all of our tests is absolutely critical because affordability does matter. It absolutely does matter. It absolutely matters to drive the uptake of our tests, but most importantly, going back to my previous comment, it absolutely matters so that we can help more people, and that's why we do what we do. Yeah. Thanks, David. Okay, related question here. What discussions have been had with private insurance providers such as Medibank, HBF, et cetera, to create awareness of the tests and how the use of the tests provides a payback that justifies them offering tests to members? Yeah. It's a good question. I'm not at liberty to share any of those discussions regarding reimbursement, either with government or with private pay at this stage, but what I can say is that we're absolutely committed to achieving reimbursement, both through the public system and the private system, to support each of our three core Promarker tests. Thank you. Okay, jumping around a bit, but it's a straightforward question here on the SPP. Will the options associated with the offer be listed on the ASX? At this stage, they will not be listed on the ASX, but we are working through our options, pardon the pun, and we will work through that and then subject to, once we get to the AGM, we will be in a better position to decide what is the best path forward. But at this stage, no. Thank you. Will there be regular monthly or quarterly webinars for shareholders? This is my second webinar. I will do them more regularly, and it will probably not be monthly, but I will consider doing that on a more regular basis moving forward. Okay. Thanks for the suggestion there. Are we seeking specific funding to make PromarkerD available to Indigenous Australians, considering the prevalence of CKD in that segment of the population? Good question. Yeah. The short answer is yes. We've had lots of discussions with Diabetes Australia. We've also had discussions with various other groups that are involved in the management of diabetes across the country, and in particular for our Indigenous population. Those discussions are ongoing, and as soon as we're in a position to share the outcomes of those discussions, we will absolutely do so. It is something that we are looking into or are in the process of discussing. Yeah, and a major unmet need. A huge unmet need. Yeah. Yep. A question on cash flow. When is it expected that Proteomics might achieve positive cash flow? That is also a good question. I am not at liberty to share our forecast, but what I would point out in the source of funds is we have not included any revenue in the source of funds, right? That is just about being conservative as it relates to the source and use of funds, but I fully expect for us to start to generate revenue very soon. The other thing that should be pointed out is, over the last nine months, and I have mentioned this, one of my first points that I mentioned in this webinar is that we have dramatically reduced our costs across the business, really significantly. Our run rate is actually a lot lower than it has ever been. I am confident that, for the most part, that will not need to increase in the near future above and beyond increase in volume that is associated with the test. I am confident we can keep that run rate at a reasonable level while still achieving all of our four critical milestones, commercial execution, appointment of initial U.S. distributor, gathering clinical evidence, reimbursement. We can continue to do that. As soon as we are cash flow positive, you will know through our 4C, and I am hoping that will be sooner rather than later. But we just have to be realistic about this. We have just launched these three tests to market. They will take time to get traction, but given the value proposition of each of these tests, I expect that to be reasonably quickly, and I expect us to generate a return also reasonably quickly. Thank you. Okay. I am conscious that we are pretty close to time. I think we earmarked about 45 minutes for this one, so we are a minute over. Let us take a couple of questions, and then I will pass back to you to close out, David, so that we can let people get on with their day. I will just say, if there was a question that you had that has not sort of largely been encapsulated in the discussion today, please do feel free to follow up directly via email, and we can work on getting a response to you. Will the Perth facility service the whole of Australia for testing? Yes. Short answer is yes. We have the capacity in Perth to do it. We have the arrangements in place to do it. Just to make that a bit real for people, the patient goes into a Healius collection center, wherever that is in the country, one of those 1,900. Their bloods get collected and processed, and then sent to their state-based collection center or processing facility. Those bloods then get batched up, get sent from each state to us in Perth as a batch. There is so much that needs to be done. It is very easy to say, "Oh, yeah, we have got a distribution partnership," and tick the box. There is an enormous amount between two organizations that needs to be set up to actually make this work, and that is all being done. The answer to the question is yes, all bloods will be collected at the Healius collection centers, and they will be sent to us in Perth to be processed. And we currently have capacity to manage our forecasted number of tests over the next 12 months. Thank you. Okay, two final questions now. Can you talk to efforts of U.S. commercialization? Yeah. We have had discussions with a number of potential distribution partners. They are ongoing, and that's all I can say at this stage, as those discussions are commercial in confidence. They will take some time to consummate, but my plan is that we will have the first initial distribution partnership in place by the end of this financial year, which is 30th of June, 2027. Okay. Final question also on other markets. Are there any reasons not to explore large markets such as India and Brazil, et cetera? Yeah. Good question. We are focused on the Australian market first and foremost for two reasons. One is, it's our home market, and we need to get traction here. We need to build a business here and be commercially successful here. Why that's important is because all of the other markets that we go to in different countries look to your home market to see how successful you are in your home market. That's one reason we focused on, or one of many reasons we focused on Australia. Second-biggest market in the world is the U.S., right? To be successful in healthcare devices, biotech, you need to be successful in the U.S. It's absolutely critical. That is our focus. Now, we have finite resources, and based on my years of experience, I know that it's very easy to get enticed by Asia Pacific or by Europe and all of these exotic countries. Actually, what's most important is we're successful in Australia, we build the U.S. market, and we're successful in the U.S. Once we've done that, and to the earlier question, and we're cash flow positive, and we're generating a really good return on our investment, then we can fund ourselves to go into those new markets. Now, those markets have just as much potential collectively as the U.S. and some of the other markets. We will pursue them, but my focus is absolutely on Australian commercial success, followed by U.S. commercial success. Great. Okay. Well, thank you. I think we got through about 25 questions on the call, and there's still quite a few in the queue, so apologies if we didn't get to you. Again, feel free to write. With that, David, I might hand back to you to any closing comments on outlook from here. Yeah, sure. Thanks, Jane. Thank you to all of you for attending this webinar. Hopefully one of many more to come. Look, I just want to reiterate that Proteomics is in the best position it has ever been in. We have a really strong foundation built on, I have to say, all of the people that have come before me, right? But we have now consolidated that and built a really, really strong foundation. We have a clear plan to drive our growth, which I'll reiterate again, is commercial execution in Australia, is U.S. market entry. It's gathering the clinical evidence to support not only awareness, but also reimbursement and focusing on reimbursement here in Australia and the U.S. In order to do that, we need to raise AUD 5 million, which will fund us through to the end of October 2027. As I mentioned earlier, that does not include any revenue we generate, which should extend our runway even further. With that, I would encourage you all to review the SPP documentation that has been now loaded up and sent. If you do have any questions or you would like to discuss anything further with me or with Jane, please reach out to Jane, and we can organize to have a discussion on a one-on-one basis. I would be really pleased to do that with any of you. Thank you very much for your time and attention, and I look forward to speaking to you all again soon. Thank you. Thanks, David. I will just say, closing that out, if you would like to get in touch, check out the ASX announcements because there are contact details at the bottom of those. As always, thanks for your support and for your time, and look forward to keeping you across Proteomics' progress. Thanks all. Have a good day.